{"organizations": [], "uuid": "1a951d0d6e0cdac01955782695af9040748282cb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-sangamo-announces-uk-authorization/brief-sangamo-announces-u-k-authorization-of-clinical-trial-evaluating-zinc-finger-nuclease-idUSASB0C7ZD", "country": "US", "domain_rank": 408, "title": "BRIEF-Sangamo Announces U.K. Authorization Of Clinical Trial Evaluating Zinc Finger Nuclease", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T14:38:00.000+02:00", "replies_count": 0, "uuid": "1a951d0d6e0cdac01955782695af9040748282cb"}, "author": "", "url": "https://www.reuters.com/article/brief-sangamo-announces-uk-authorization/brief-sangamo-announces-u-k-authorization-of-clinical-trial-evaluating-zinc-finger-nuclease-idUSASB0C7ZD", "ord_in_thread": 0, "title": "BRIEF-Sangamo Announces U.K. Authorization Of Clinical Trial Evaluating Zinc Finger Nuclease", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.k.", "sentiment": "none"}], "organizations": [{"name": "sangamo", "sentiment": "none"}, {"name": "sangamo therapeutics inc", "sentiment": "none"}, {"name": "nuclease reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "sangamo therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 40 PM / in 9 minutes BRIEF-Sangamo Announces U.K. Authorization Of Clinical Trial Evaluating Zinc Finger Nuclease Reuters Staff 1 Min Read Feb 28 (Reuters) - Sangamo Therapeutics Inc: * SANGAMO ANNOUNCES U.K. AUTHORIZATION OF CLINICAL TRIAL EVALUATING ZINC FINGER NUCLEASE IN VIVO GENOME EDITING TREATMENT FOR HEMOPHILIA B * SANGAMO THERAPEUTICS INC - EXPECTS TO INITIATE SITES IN U.K. LATER THIS YEAR FOR SB-FIX PHASE 1/2 CLINICAL TRIAL​ * SANGAMO THERAPEUTICS INC - ‍EXPECTS TO FILE ADDITIONAL CTAS FOR SB-318 & SB-913 IN VIVO GENOME EDITING TREATMENTS FOR MPS I AND MPS II, RESPECTIVELY​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)", "external_links": [], "published": "2018-02-28T14:38:00.000+02:00", "crawled": "2018-02-28T15:04:29.013+02:00", "highlightTitle": ""}